Immunic (IMUX) Change in Acquisitions & Divestments (2013 - 2023)

Immunic (IMUX) posted Change in Acquisitions & Divestments of $4.4 million for Q2 2023, down 19.89% sequentially from $5.4 million in Q1 2023.

Analysis

Immunic (IMUX) Change in Acquisitions & Divestments (2013 - 2023) Analysis & Trends

Immunic has reported Change in Acquisitions & Divestments for 2 years, with the latest figure at $4.4 million in Q2 2023.

Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $4.4 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9.8 million (up 95.88% YoY) and the FY2013 annual result came in at $17.0 million, changed N/A from the prior year.
Change in Acquisitions & Divestments retreated to $4.4 million in Q2 2023 per IMUX's latest filing, from $5.4 million in the prior quarter.
Over five years, Change in Acquisitions & Divestments peaked at $5.4 million in Q1 2023 and troughed at $4.4 million in Q2 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Immunic	546.30 Mn	546.30 Mn	-

Historic Data

Download Data